Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation

References

• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119(3):e21-181
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial Fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147(9):1561-4
   PubMedGoogle Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota 1980 to 2000, and implications on the projections for further prevalence. Circulation 2006;114:119-25
   PubMed Web of Science ®Google Scholar
• Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154(17):1945-53
   PubMedGoogle Scholar
• Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3Suppl):287S-310S
   Google Scholar
• Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009;54:999-1002
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):901-92
   Google Scholar
• Giugliano RP, Ruff CT, Bruanwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104
   PubMed Web of Science ®Google Scholar
• Bruins Slot KM, Berge E. Factor Xa Inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2013;(8):CD008980
   Google Scholar
• Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61(2):755-9
   PubMed Web of Science ®Google Scholar
• Katz ES, Tsiamtsiouris T, Applebaum RM, et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. J Am Coll Cardiol 2000;36:468-71
   PubMed Web of Science ®Google Scholar
• Madden J. Resection of the left auricular appendix. JAMA 1948;140:769-72
   Google Scholar
• Bailey C, Olsen A, Keown K, et al. Commissurotomy for mitral stenosis technique for prevention of cerebral complications. JAMA 1952;149:1085-1091.16
   PubMedGoogle Scholar
• Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011;57:e101-98
   PubMed Web of Science ®Google Scholar
• Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007;4:816-61
   PubMed Web of Science ®Google Scholar
• Cox JL. The surgical treatment of atrial fibrillation, IV: surgical technique. J Thorac Cardiovasc Surg 1991;101:584-92
   PubMed Web of Science ®Google Scholar
• Johnson WD, Ganjoo AK, Stone CD, et al. The left atrial appendage: our most lethal human attachment: surgical implications. Eur J Cardiothorac Surg 2000;17:718-22
   PubMed Web of Science ®Google Scholar
• Nakai T, Lesh MD, Gerstenfeld EP, et al. Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: first experience in canine model. Circulation 2002;105(18):2217-22
   PubMed Web of Science ®Google Scholar
• Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105(16):1887-9
   PubMed Web of Science ®Google Scholar
• Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005;46(1):9-14
   PubMed Web of Science ®Google Scholar
• Holmes DR, Reddy VY, Turi ZG, et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374(9689):534-42
   PubMed Web of Science ®Google Scholar
• Waksman R, Pendyala L. Overview of the Food and Drug Administration Circulatory System Devices Panel Meetings on WATCHMAN Left Atrial Appendage Closure Therapy. Am J Cardiol 2015;115:378e 384
   Google Scholar
• Lee R. Evolution of Stroke Prevention in Nonvalvular Atrial Fibrillation Patients. JACC 2014;64(1):13-15
   Google Scholar
• Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman LAA closure device in patients with atrial fibrillation versus long term warfarin therapy trial (PREVAIL). J Am Coll Cardiol 2014;64(1):1-12
   PubMed Web of Science ®Google Scholar
• Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123(4):417-24
   PubMed Web of Science ®Google Scholar
• Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014;312(19):1988-98
   PubMed Web of Science ®Google Scholar
• Singh SM, Micieli S, Wijeysundera HC. An economic evaluation of percutaneous left atrial appendage occlusion: Dabigatran and warfarin for stroke prevention in patients with non-valvular atrial fibrillation. Circulation 2013;127(24):2414-23
   PubMed Web of Science ®Google Scholar
• Meier B, Palacios I, Windecker S, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003;60:417-22
   PubMed Web of Science ®Google Scholar
• Park JW, Bethencourt A, Sievert H, et al. Left Atrial Appendage closure With Amplatzer Cardiac Plug in Atrial Fibrillation: Initial European Experience. Catheter Cardiovasc Interv 2011;77:700-6
   PubMed Web of Science ®Google Scholar
• Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 2015;10(10):1-10
   Google Scholar
• Meier B, Blaauw Y, Khattab A, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 2014;16:1397-416
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383(9921):955-62
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-17
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. LARIAT Loop Applicator, 510(k) summary. 2006. Available from: www.accessdata.fda.gov/cdrh_docs/pdf6/K060721.pdf
   Google Scholar
• US Food and Drug Administration. LARIAT Loop Applicator, 510(k) summary. 2009. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K09038538
   Google Scholar
• US Food and Drug Administration. LARIAT Loop Applicator, 510(k) summary. 2014. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K14224139
   Google Scholar
• Lee RJ, Bartus K, Yakubov SJ. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model. Circ Cardiovasc Interv 2010;3:224-9
   Google Scholar
• Singh SM, Dukkipati SR, d’Avila A, et al. Percutaneous left atrial appendage closure with an epicardial suture ligation approach: a prospective randomized pre-clinical feasibility study. Heart Rhythm 2010;7:370-6
   Google Scholar
• Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm 2011;8:188-93
   Google Scholar
• Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2013;62(2):108-18
   PubMed Web of Science ®Google Scholar
• Massumi A, Chelu MG, Nazeri A, et al. Initial Experience With a Novel Percutaneous Left Atrial Appendage Exclusion Device in Patients With Atrial Fibrillation, Increased Stroke Risk, and Contraindications to Anticoagulation. Am J Cardiol 2013;111(6):869-73
   Web of Science ®Google Scholar
• Stone D, Byrne T, Pershad A. Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation. Catheter Cardiovasc Interv 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 2014;64(6):565-72
   Web of Science ®Google Scholar
• Miller MA, Gangireddy SR, Doshi SK, et al. Multicenter study on acute and long-term safety and efficacy of percutaneous left atrial appendage closure using an epicardial suture snaring device. Heart Rhythm 2014;11(11):1853-9
   Google Scholar
• Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm 2015; Epub ahead of print
   Google Scholar
• Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012;59(10):923-9
   PubMedGoogle Scholar
• Koneru JN, Badhwar N, Ellenbogen KA, Lee RJ. LAA ligation using the LARIAT suture delivery device: tips and tricks for a successful procedure. Heart Rhythm 2014;11(5):911-21
   Google Scholar
• Bartus K, Morelli RL, Szczepanski W, et al. Anatomic analysis of the left atrial appendage after closure with the LARIAT device. Circ Arrhythm Electrophysiol 2014;7(4):764-7
   PubMed Web of Science ®Google Scholar
• Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61(25):2551-6
   PubMed Web of Science ®Google Scholar
• Stollberger C, Schneider B, Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? Anatomic, physiologic, and pathophysiologic considerations. Chest 2003;124(6):2356-62
   Google Scholar
• Rodeheffer RJ, Naruse M, Atkinson JB, et al. Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation 1993;88:364-71
   Google Scholar
• Inoue S, Murakami Y, Sano K, et al. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000;6:92-6
   PubMed Web of Science ®Google Scholar
• Nakamura M, Niinuma H, Chiba M, et al. Effect of the Maze procedure for atrial fibrillation on atrial and brain natriuretic peptide. Am J Cardiol 1997;79:966-70
   Google Scholar
• Yoshihara F, Nishikimi T, Kosakai Y, et al. Atrial natriuretic peptide secretion and body fluid balance after bilateral atrial appendectomy by the Maze procedure. J Thorac Cardiovasc Surg 1998;116:213-19
   Google Scholar
• Ito T, Suwa M, Kobashi A, et al. Influence of altered loading conditions on left atrial appendage function in vivo. Am J Cardiol 1998;81:1056-9
   PubMed Web of Science ®Google Scholar
• Maybrook R, Pillarisetti J, Yarlagadda V, et al. Electrolyte and hemodynamic changes following percutaneous left atrial appendage ligation with the LARIAT device. J Interv Card Electrophysiol 2015; Epub ahead of print
   Google Scholar
• Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation 2010;122:109-18
   PubMed Web of Science ®Google Scholar
• Hocini M, Shah AJ, Nault I, Sanders P. Localized reentry within the left atrial appendage: arrhythmogenic role in patients undergoing ablation of persistent atrial fibrillation. Heart Rhythm 2011;8(12):1853-61
   Google Scholar
• Han FT, Bartus K, Lakkireddy DJ, et al.The Effects of LAA Ligation on LAA. Electrical Activity. Heart Rhythm 2014;11:864-70
   PubMed Web of Science ®Google Scholar
• Kawamura M, Scheinman MM, Lee RJ, Badhwar N. Left atrial appendage ligation in patients with atrial fibrillation leads to a decrease in atrial dispersion. J Am Heart Assoc 2015; Epub ahead of print
   Google Scholar
• Afzal MR, Kanmanthareddy A, Earnest M, et al. Impact of Left Atrial Appendage Exclusion Using an Epicardial Ligation System (LARIAT) on Atrial Fibrillation Burden in Patients with Cardiac Implantable Electronic Devices. Heart Rhythm 2014; [Epub ahead of print]
   Google Scholar
• Badhwar N, Lakkireddy D, Kawamura M, et al.Sequential Percutaneous LAA. Ligation and Pulmonary Vein Isolation in Patients with Persistent AF: Initial Results of a Feasibility Study. J Cardiovasc Electrophysiol 2015;10.1111/jce.12655. [Epub ahead of print]
   Google Scholar
• Lakkireddy D, Mahankali AS, Kanmanthareddy A, et al. Left Atrial Appendage Ligation and Ablation for Persistent Atrial Fibrillation (LAALA-AF Registry). Accepted in JACC EP
   Google Scholar